Compare · ARGX vs TARA
ARGX vs TARA
Side-by-side comparison of argenx SE (ARGX) and Protara Therapeutics Inc. (TARA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TARA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.42B, about 171.4x TARA ($282.5M).
- Over the past year, ARGX is up 25.7% and TARA is up 46.5% - TARA leads by 20.8 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- ARGX has more recent analyst coverage (25 ratings vs 6 for TARA).
- Company
- argenx SE
- Protara Therapeutics Inc.
- Price
- $780.08-1.00%
- $5.13-2.38%
- Market cap
- $48.42B
- $282.5M
- 1M return
- +11.90%
- -3.20%
- 1Y return
- +25.72%
- +46.50%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2014
- News (4w)
- 2
- 2
- Recent ratings
- 25
- 6
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Protara Therapeutics Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
- SEC Form 6-K filed by argenx SE
Latest TARA
- SEC Form PRE 14A filed by Protara Therapeutics Inc.
- SEC Form 4 filed by Zummo Jacqueline
- SEC Form 4 filed by Zummo Jacqueline
- Protara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 10-K filed by Protara Therapeutics Inc.
- Protara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
- SEC Form 424B7 filed by Protara Therapeutics Inc.
- Analyst initiated coverage on Protara Therapeutics with a new price target
- SEC Form SCHEDULE 13G filed by Protara Therapeutics Inc.